WO2018211336A3 - Solid dosage form containing sorafenib tosylate - Google Patents
Solid dosage form containing sorafenib tosylate Download PDFInfo
- Publication number
- WO2018211336A3 WO2018211336A3 PCT/IB2018/001009 IB2018001009W WO2018211336A3 WO 2018211336 A3 WO2018211336 A3 WO 2018211336A3 IB 2018001009 W IB2018001009 W IB 2018001009W WO 2018211336 A3 WO2018211336 A3 WO 2018211336A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- solid dosage
- sorafenib tosylate
- form containing
- containing sorafenib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a solid dosage form containing Sorafenib tosylate which is used in pharmacy and medicine. An advantage of the composition according to the invention is improved bioavailability and tolerability, possibility of its applicable at lower optimal therapeutic doses that created balance between reduction of adverse drug reactions and abilility to overcome acquired resistance in the course of therapy. A solid dosage form, according to the invention, comprising Sorafenib tosylate, a precipitation inhibitor in an amount of 0.5 to 25% by weight, preferably from 0.5% to 15%, and most preferably from 1% to 10% and optionally other excipients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/001009 WO2018211336A2 (en) | 2018-09-07 | 2018-09-07 | Solid dosage form containing sorafenib tosylate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/001009 WO2018211336A2 (en) | 2018-09-07 | 2018-09-07 | Solid dosage form containing sorafenib tosylate |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018211336A2 WO2018211336A2 (en) | 2018-11-22 |
WO2018211336A3 true WO2018211336A3 (en) | 2019-06-13 |
Family
ID=63683233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/001009 WO2018211336A2 (en) | 2018-09-07 | 2018-09-07 | Solid dosage form containing sorafenib tosylate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018211336A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114916221B (en) * | 2020-12-07 | 2024-01-30 | 天津睿创康泰生物技术有限公司 | Sorafenib pharmaceutical composition with high bioavailability and application |
WO2023155182A1 (en) | 2022-02-21 | 2023-08-24 | 北京睿创康泰医药研究院有限公司 | Low-dose, high-exposure sorafenib or donafenib oral formulation and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006094626A1 (en) * | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
UA91520C2 (en) | 2004-09-29 | 2010-08-10 | Баер Шеринг Фарма Акциенгезельшафт | Thermodynamically stable form of tosylate |
TW200820991A (en) | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
-
2018
- 2018-09-07 WO PCT/IB2018/001009 patent/WO2018211336A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006094626A1 (en) * | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
Non-Patent Citations (2)
Title |
---|
DR T MANGILAL: "Formulation and evaluation of sorafenib tosylate immediate release", WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, IN, vol. 4, June 2015 (2015-06-01), pages 841 - 858, XP009512848, ISSN: 2277-7105 * |
MALLIKARJUN V: "In-vitro and kinetic studies of immediate release sorafenib tosylate film coated tablets", WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, IN, vol. 7, May 2018 (2018-05-01), pages 931 - 944, XP009512849, ISSN: 2277-7105 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018211336A2 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124878T1 (en) | ORODIZED DOSAGE UNIT CONTAINING AN ESTETROL INGREDIENT | |
EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
MX2019012884A (en) | Combination therapy. | |
EA201691454A1 (en) | COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING | |
AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
PH12018501001A1 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
MX2015016112A (en) | Tamper-resistant dosage form containing one or more particles. | |
JO3784B1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
PH12020550341A1 (en) | Niraparib formulations | |
CY1124532T1 (en) | DOSAGE FORMS FOR ANTI-TF DRUG-ANTIBODY CONJUGATIONS | |
EA201792592A1 (en) | PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN | |
EA201800499A1 (en) | THYROZINKINASE INHIBITOR FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS, COMPOSITION, MEDICINE, SET | |
MX2017010280A (en) | Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them. | |
MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
BR112018012870A2 (en) | methods and compositions for the treatment of crisis-related disorders | |
MX2018000084A (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin. | |
MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
WO2018211336A3 (en) | Solid dosage form containing sorafenib tosylate | |
MX2019005104A (en) | Zinc-y-pga compositions and methods for treating cancer. | |
MX2020010119A (en) | Anti-cd27 antibody, antigen-binding fragment thereof and medical use thereof. | |
MX2016008027A (en) | Use of laquinimod to delay huntington's disease progression. | |
MX2015009546A (en) | Increased dosage of efavirenz for the treatment of cancer. | |
MX2022001802A (en) | Methods for increasing the bioavailability of otc and pharmaceutical drugs. | |
MX2020002247A (en) | LONG-ACTING PALMITIC ACID-CONJUGATED GnRH DERIVATIVE, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18774107 Country of ref document: EP Kind code of ref document: A2 |